Your shopping cart is empty!
Ora Mune and Derma Mune products, produced by Immune Therapy Research, are the best supplements in the field at supporting the immune system. They contain ingredients supported by a signifcant body of scientific evidence and work towards promoting optimal health without any side effects. Immune Therapy Research Laboratory was founded by Said Youdim PhD., the current director of research and development. Dr. Youdim received his bachelor’s degree in Microbiology from the university of California in Los Angeles and his doctoral degree in immunology and biochemistry from Baylor University. He received further training as a postdoctoral fellow in cellular and clinical immunology at the university of Minnesota and UCLA.
Dr. Youdim then gained a faculty position at the University of California San Diego where he continued his research in cellular and cancer immunobiology. He later became interested in clinical immunology and immune therapy that he currently pursues. He has lectured extensively, authored many research publications in basic and clinical immunology and worked at a large number of clinics as a consultant. He has developed a number of protocols for diagnostic immunology and immune therapy and has conducted extensive published clinical trials. Dr. Youdim currently collaborates with many physicians, health care practitioners, and researchers.
His line of products are recommended by many health care professionals through the United States and United Kingdom as potent immune stimulants and immune modulators. There is a substantial wealth of evidence that supports the ingredients that go into all the Oramune products, which can be found below.
Transfer Factor
1. Lawrence HS. The transfer in humans of delayed sensitivity to Sreptococcal M substance and tuberculin with disrupted leukocytes. J Clin Invest 34:219-232, 1955.
2. Kahn A, Nagata K, hill No. et al. Management of viral infections with transfer factor. In Kahn A, Kirkpatrick CH, Hill NO, eds. Immune regulators in transfer factor. New York: Academic Press, 501-511, 1974.
3. Shulman ST, Hutio JH, Scott B. Transfer factor therapy of chronic aggressive hepatitis. In Archer MS, Gottlieb AA, Kirkpatrick CH, eds. Transfer factor. Basic properties and clinical applications. New York: Academic Press, 439-448, 1976.
4. Visa D, Vich JM, Phillips J, Rosenfeld F. Orally administered specific transfer factor for the treatment of herpes infections. Lymphokine Res. 4:27-30, 1985.
5. Meduri R, Campos E, Scrolli C, et al. Efficacy of transfer factor in treating patients with recurrent ocular herpes infections. Biotherapy 9:61-66, 1996.
6. Pizza G, Visa D, De Vinci C. Orally administered HSV- specific transfer factor prevents genital or labial herpes relapses. Biotherapy 9:67-72, 1996.
7. Jones JF, Wayburn SJ, Fulgitini VA. Treatment of childhood combined Epstein Barr virus/ Cytomegalovirus infection with oral bovine transfer factor. Lancet July 18, 1981.
8. Neequaye J, Viza D, Pizza G, Levine PH, et al. Specific transfer factor with activity against Epstein- Barr virus reduces late relapse in endemic Burkitt’s lymphoma. Anti-Canc. Res. 10:1183-1187, 1990.
9. Parsad U, Bin Jalaludin MA, Rajaduri P, Pizza G, De Vinci C, Vizza D, Levine PH. Transfer factor with anti- EBV activity as an adjuvant therapy for nasopharyngeal carcinoma: A pilot study. Biotherapy 9:109-115,1996.
10. Viza D, Lefesvre A, Patrasco M, et al. A preliminary report on three AIDS patients treated with Anti- HIV specific transfer factor. J. Exp. Path. 3:653-659,1987.
11. Viza D. AIDS and transfer factor: Myths, certainties, and realities. Biotherapy 9:17-26, 1996.
12. Gottlieb AA, Sizemore RC, Gottlieb MS, Kern CH. Rationale and clinical results for using leukocyte derived immunosupportive therapies in HIV disease. Biotherapy 9:27-31, 1996.
13. Berron R, Almedarez C, Rosiles G. Suppurative adenopathy by salmonella B treated with transfer factor. Case report. http:/itfs.med.unibo.it/itfs/
14. Louie E, Borkowsky W, Klesius PH. Treatment of Cryptosporidiosis with oral bovine transfer factor. Clin. Immunol. and Immunopath. 44:329-334, 1987.
15. Mc Meeking A, Borkowsky W, Klesius PH, etal. A controlled trial of bovine dialyzable leukocyte extract for Cryptosporidiosis in patients with AIDS. J. Inf. Dis. 161:108-112, 1990.
16. Littman BH, Ross ER, Parkman R, etal. Transfer factor- amphotericin B therapy in case of chronic mucocutaneous candidiasis. A controlled study. In Archer MS, Gottlieb AA, Kirkpatrick CH, eds. Transfer factor. Basic properties and clinical applications. New York: Academic Press, 495, 1976.
17. Ballow M, Hyman L. Immunological reconstitution of chronic mucocutaneous candidiasis with Transfer factor and fetal thymic tissue. In Archer MS, Gottlieb AA, Kirkpatrick CH. eds. Transfer factor. Basic properties and clinical applications. New York: Academic Press, 501, 1976.
18. Kirkpatrick CH, Greenburg LE. Treatment of chronic mucoctaneous candidiasis with transfer factor. In Archer MS, Gottlieb AA, Kirkpatrick CH. eds. Transfer factor. Basic properties and clinical applications. New York: Academic Press, 547, 1976.
19. Masi M, De Vinci C, Baricorddi OR. Transfer factor in mucoctaneous candidiasis. Biotherapy. 9: 97-103, 1996.
20. Visa D. Can specific transfer factor be an effective treatment for CFS? The CFIDS chronicle, Physicians forum Fall, 1993.
21. Levine PH. The use of transfer factor in Chronic Fatigue Syndrome: Prospects and problems. Biotherapy. 9: 77-79, 1996.
22. De Vinci C, Levine PH, Pizza G. et al. Lessons from pilot study of transfer factor in Chronic Fatigue Syndrome. Biotherapy, 9: 87-90, 1996.
23. Hana I, Vrubel J, Pekarek J and Cech K. The influence of age on transfer factor treatment of cellular immunodeficiency, Chronic Fatigue Syndrome and /or chronic viral infections. Biotherapy. 9: 91-95, 1996.
24. Whitaker JA, Dopson MH, Mattman LH. et al. Preliminary study of transfer factor ( T.F.) in patients with Fibromyalgia (Fm), Chronic Fatigue Syndrome (Cf), and concomitant Lyme Borreliosis. http://itfs. med.unibo.it/itfs/
25. Youdim S, Rea WJ, Liang CH. Treatment of environmentally sensitive patients with transfer factor. Part I: Immunologic studies. Clin.Ecol. 7:55-61, 1990.
26. Youdim S, Rea WJ. Treatment of environmentally sensitive patients with transfer factor. Part II: Clinical studies and immunological correlates. 7: 62-66, 1990.
27. Youdim S, Liang CH, Rea WJ. Treatment of of environmentally sensitive patients with transfer factor. Part III: Case studies on three patients. 7: 67-72,1990.
28. Navaro-Cruz D, Serrano–Miranda E, Orea-s s. et al. Transfer factor as a good therapeutic agent in moderate and severe atopic dermatitis. http://itfs.med.unibo.it/itfs/
29. Cordero-Miranda MA. Serrano–Miranda E. Flores-Sandoval G. et al. Treatment of atopic dermatitis with transfer factor and cyclosporine A. http://itfs.med.unibo.it/itfs/
30. Jones JF, Jeter WS, Hicks MJ, et al. Oral transfer factor (OTF) use in the hyper IgE syndrome. In Kirkpatrick CH, Brger DR, Lawrence HS,. eds. Immunobiology of transfer factor. New York: Academic Press, 261-269, 1983.
31. Ayla-De La Cruz MC, Rodrirguez-Padilla C, Tamaz Guerra R. Management of hypereosinophilia with transfer factor. http://itfs.med.unibo.it/itfs/
32. Fudenberg HH. Strlkauskas AJ. Goust JM. et al. Discoid lupus erythmatosus: Dramatic clinical and immunological response to dialyzable leukotcyte extract (transfer factor) Trans. Assoc. Am. Phys. 94: 279-291, 1981.
33. Grohn P, Raimo A, Krohn K. The effect of chromatographically purified Transfer factor component on juvenile Rheumatoid Arthritis. In Archer MS, Gottlieb AA, Kirkpatrick CH. eds. Transfer factor. Basic properties and clinical applications.
New York: Academic Press, 613, 1976.
34. Cozine WS, Stanfield AB, Stephens C.A.L. Transfer factor immunotherapy of Rheumatoid Arthritis. In Archer MS, Gottlieb AA, Kirkpatrick CH. eds. Transfer factor. Basic properties and clinical applications. New York: Academic Prss, 617, 1976.
35. McLeod JG, Basten A, Pollard JD. et al. Transfer factor in the treatment of multiple sclerosis. Clin. Exp. Neurol. 17: 240, 1980.
36. Nevismal O, Pekarek J, Koubek K, et al. Low molecular transfer factor and it’s use in the treatment of amyotrophic lateral sclerosis. Cesk. Neurol. Nerochir. 54: 220-223, 1990.
37. Khan A, Hill JM, Piga S, Antone Hi AL. Transfer factor in Guillian-Barre syndrome. Arch. Neurol. 36: 1997.
38. Fudenberg. HH. Dialyzable lymphocyte extract (DlyE) in infantile onset autism: A pilot study. Biotherapy. 9: 143-147, 1996.
Colostrum
39. Korhonen H, Syvaoja EL, Ahola-Luttila H, etal. Bactericidal effect of bovine normal and immune serum, colostrum and milk against Helicobacter pylori. (6): 655-662, 1995.
40. Rump JA, Aondt R, Arnold A, et al. Treatment of diarrhea in human immunodeficiency virus infected patients with immunoglobulins from bovine colostrum. Clin Investigator 70: 588-94, 1992.
41. Flanigan T., Marshal R., Rodman D. et al. In vitro screening of therapeutic agents against Cryptosporidium: hyperimmune cow colostrum is highly inhibitory. J. Protozoology 38: 225 S-227 S, 1991.
42. Stephan W., Dichtelmuller H., Lisser R. Antibodies from colostrum in oral immunotherapy. J. Clin. Chem. And Clin. Biochem. 28: 19-23, 1990. Cytokines
43. Przmioslo RT, Cliclitera PJ. Cytokines and gastrointestinal disease mechanisms. Bailieres Clin Gastroenterol 10: 17-32, 1996.
44. Garofalo RP, Glodman AS. Cytokines, Chemokines, and colony stimulating factors in human milk: the 1997 update. Biol Neonate 74: 134-142, 1998.
45. Dinarello CA. The interleukin-1 family: 10 years of discovery. FASEB J 8:1314-1325, 1994.
46. Kanderfer S. In vitro and In vivo intereferon production by Bovine colostrol leukocytes. DTSCH Tierartzl, Wochenschr. 98: 395- 398, 1991.
47. Lawton JW etal. Interferon synthesis by human colostrol leukocytes. Arch Dis child. 54: 127-130, 1979.
Lactoferrin
48. Nikawa H, Samaranayke LP, Tenovuo J. the fungicidal effect of human lactorferrin on Candida albicans and Candida krusei. Archives of oral biology. 38: 1057-1063, 1997.
49. Bellamy W. Wakaboyashi H, Takase M. et al. Killing of Candida albicans by lactoferrin B, a potent antimicrobial peptide derived from the N- terminal region of bovine lactoferrin. Med. Microb and Immunal. 182: 97- 105, 1993.
50. Hasegawo K, Motsuki W, Tanaka S, et al. Inhibition with lactroferrin of in vitro infection with human herpes virus. Japanese J. Med. Sci. and Bio. 47: 73-85, 1994.
51. Martin C, Harmsen PJ, Swart MP, et al. Antiviral effects of plasma and milk proteins: Lactoferrin shows potent activity against the human immunodeficiency virus and human cytomegalovirus replication in vitro. J. Infections Dis. 172:380-383, 1995.
52. Togawa J, Nagase H, Tanaka K. et al. Oral administration of lactoferrin reduces colitis via modulation of immune system and correction of cytokine imbalance. J. Gastroenterol. Hepatol. 17: 1291-1298, 2002.
53. Tagowa J, Nagase H, Tanaka K. et al. Lactoferrin reduces colitis in rats via modulation of the immune system and correction of cytokine imbalance. Am. J. Physiol. Gastrointest. Liver Physiol. 283: 187-195, 2002.
54. Harversen L A, Baltzer L, Dolphin G. et al. Anti-inflammatory activities of human lactoferrin in acute dextran suphate-induced colitis in mice. Scand J. Immunol. 57:2-10, 2003.
Growth Factors
55. Read LC, Francis GL, Wallace JC, Ballard FJ. Growth factor concentrations and growth- promoting activity in human milk following premature birth. J Dev Physiol 7: 135-145, 1985.
56. Koldovsky O, Britton J, Davis D, et al. The developing gastrointestinal tract and milk-borne epidermal growth factor. In: Mestecky J, ed. Immunology of milk and neonate. New York: Plenum Press, 99-105, 1991.
57. Cartlidge SA, Elder JB. Transforming growth factor alpha and EGF levels in normal human gastrointestinal mucosa. Br J Cancer 60: 657-660, 1989.
58. Koyama S, Podolsky DK. Differantial expression of transforming growth factors alpha and beta in rat intestinal epithelial cells. J Clin Invest 83: 1768-1773, 1989.
59. Shing YW, Klagsbrun M. human and bovine milk contain different set of growth factors. Endocinology 115: 273-282, 1984.
60. Siafakas CG, Anatolitou F, Funsunyan RD, Walker WA, Sanderson IR. Vascular endothelial growth factor (VEGF) is present in human breast milk and its receptor is present on intestinal epithelial cells. Pediatr. Res. 45:652-657, 1999.
B1,3/1,6 Glucan
61. Manners DJ, Mason AJ, Patterson JC. The structure of B- (1-3) glucan from yeast cell walls. Biochem. J. 135: 19-30, 1973.
62. DiLuzio NR, McNaffec R, Jones E, et al. The employment of glucan and glucan activated macrophages in enhancement of host resistance to malignancies in experimental animals. In: MD Fink (ed) the macrophage in Neoplasia. 121-198, Academic Press, New York,1976.
63. Diluzio NR, Williams DL, McNamee TLB, et al. Comparative tumor-inhibotory and anti bacterial activity of soluble and particulate glucan. Int. J, Cancer 24: 773-779, 1979.
64. Patchen ML, Macvittie TJ, Brook I. Glucan- induced hemopoietic and immune stimulation: therapeutic effects in sub-lethally and lethally irradiated mice. Methods Find Exp Clin Pharmacol 8:151-155, 1986.
65. Abel G, Czop JC. Stimulation of human monocy te beta- glucan receptors by glucan particles induces production of TNF- alpha and IL- I beta. Int. J. Immunopharmoc 14:1363-1373, 1992.
66. Macela A, Lesna J, Kovarovou H. modulatory effect of glucans on the function of murine macrophages, NK- cells and lymphocytes. Bratise Lek Listy 92: 283-290, 1991. Chicken Egg
Chicken Egg Yolk Antibody (IgY)
67. Loch U, Schranner I, Wanke R, et al. The chicken egg and antibody source. J. Vet. Med B 33: 609-919, 1986.
68. Peralta RC, Yokoyama H, Ikemori Y. et al. Passive immunization against salmonellosis in mice by orally administered hen egg yolk antibodies specific for 14-KD a fimbriae of salmonella enderitidis. J. Med. Microbiol 41: 29-35, 1994.
69. Ikemori Y, Ohta M, Umeda K, et al. Passive protection of neonatal calves against bovine corona virus- induced diarrhea by administration of egg yolk or colostrum antibody powder. Vet. Microbiol. 58: 105-111, 1997.
70. Schmidt P, Wiedmann V, Kuhlmann R, et al. Chicken egg antibodies for prophylaxis and therapy of infectious intestinal diseases. II. In vitro studies on gastric and enteric digestion of egg yolk antibodies specific against pathogenic Eschorichia coli strains. J. Vet. Med B 36: 619- 628, 1989.
71. Shimizu M, Fitzsimmons RC, Nakai S, Anti E. coli immunoglobulin Y isolated fromm egg yolk of immunized chickens as a potential food ingredient. J. Food Sci 53: 1360-1366: 1988.
72. Yolken RH, Leister F, Wee S-B, et al. Antibodies to Rota viruses in chicken eggs. A potential source of antiviral immunoglobulins suitable for human consumption. Pediatrics 82: 291-295, 1988.
73. Hatta H, Tsuda K, Ozaki M, et al. Passive immunization against dental plaque formation in humans: Effect of a mouth rinse containing egg yolk antibodies (IgY) specific for Strepcoccus mutans, Carrier Res 31: 268- 274, 1997.
Inflammatory Cytomines - TNF
74. Komatsu M, Kobayashi D, Saito K. et al. Tumor necrosis factor-alpha in serum of patients with inflammatory bowel disease as measured by a highly sensitive immuni-PCR, Clin. Chem. 47:1297-1301, 2001.
75. Louis E. The immuno-inflammatory reaction in Crohn's disease and ulcerative colitis: Characterisation, genetics and clinical application. Focus on TNFalpha. Acta. Gastroenterol. Belg. 64:1-5, 2001.
76. Hommes DW, van Deventer S J. Targeting tumor necrosis factor alpha in inflammatory bowl disease: Why, how and when? Curr. Opin. Gastroenterol. 19:350-357, 2003.
TNF inhibitors and Antibodies
77. Blam E M, Stein R B, Lichtenstein G R. Integrating anti-tumor necrosis factor therapy in inflammatory bowl disease. Current and future perspectives. Am. J. Gastroenterol. 96:1977-1997, 2001.
78. Ganesan S, Travis SP, Ahmad T, Jazrawi R. Therapeutic inhibitors of tumor necrosis factor in Crohn's disease. Curr. Open. Investig. Drugs. 3:1301-1306, 2002.
79. Mamula P, Cohen SA, Ferry G D et al. CDP571, a humanized anti-tumor necrosis factor aloha monoclonal antibody in pediatric Crohn's disease. Inflamm. Bowel Dis 10:723-730, 2004.
80. Rutgeerts PJ, D'Haens G, Targan S. et al. Efficacy and safety of treatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 117:761-769, 1999.
81. Worledge KL, Godiska R, Terrence A. et al. Oral administration of avian tumor necrosis factor antibodies effectively treats experimental colitis in rats. Digestive disease and Sciences 45: 2298-2305, 2000.
